Janssen-Cilag GmbH

EFFICACY AND SAFETY OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO DEMONSTRATED INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITION: WEEK 24 RESULTS OF A PHASE 3B, RANDOMIZED, CONTROLLED STUDY (2021) Coates LC, Gossec L, Theander E, Bergmans P, Neuhold M, Karyekar C, Shawi M, et al. Conference contribution Real-world effectiveness of guselkumab in patients with psoriasis: Health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial (2021) Gerdes S, Bräu B, Hoffmann M, Korge B, Mortazawi D, Wiemers F, Wegner S, et al. Journal article Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy (2021) Tully KH, Jütte H, Wirtz RM, Jarczyk J, Santiago-Walker A, Zengerling F, Breyer J, et al. Journal article Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS) (2020) Thaci D, Pinter A, Sebastian M, Termeer C, Sticherling M, Gerdes S, Wegner S, et al. Journal article Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials (2019) Straka C, Knop S, Vogel M, Müller J, Kropff M, Metzner B, Langer C, et al. Journal article Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA (2019) Janssens R, Russo S, van Overbeeke E, Whichello C, Harding S, Kübler J, Juhaeri J, et al. Journal article Default mode network connectivity change corresponds to ketamine's delayed glutamatergic effects (2018) Li M, Woelfer M, Colic L, Safron A, Chang C, Heinze HJ, Speck O, et al. Journal article Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma (2017) Einsele H, Knop S, Vogel M, Mueller J, Kropff M, Metzner B, Langer C, et al. Journal article Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial (2017) Einsele H, Engelhardt M, Tapprich C, Mueller J, Liebisch P, Langer C, Kropff M, et al. Journal article Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT) (2014) Paul C, Puig L, Kragballe K, Luger T, Lambert J, Chimenti S, Girolomoni G, et al. Journal article